GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ovation Science Inc (XCNQ:OVAT) » Definitions » Debt-to-Asset

Ovation Science (XCNQ:OVAT) Debt-to-Asset : 3.87 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ovation Science Debt-to-Asset?

Ovation Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$0.21 Mil. Ovation Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was C$0.05 Mil. Ovation Science's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was C$0.07 Mil. Ovation Science's debt to asset for the quarter that ended in Sep. 2024 was 3.87.


Ovation Science Debt-to-Asset Historical Data

The historical data trend for Ovation Science's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovation Science Debt-to-Asset Chart

Ovation Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial 0.13 - - 0.39 2.49

Ovation Science Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 2.49 2.60 3.02 3.87

Competitive Comparison of Ovation Science's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovation Science's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ovation Science's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ovation Science's Debt-to-Asset falls into.


;
;

Ovation Science Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ovation Science's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Ovation Science's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovation Science  (XCNQ:OVAT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Ovation Science Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ovation Science's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovation Science Business Description

Traded in Other Exchanges
Address
1166 Alberni Street, Suite 1003, Vancouver, BC, CAN, V6E 3Z3
Ovation Science Inc. is a Canada-based company mainly engaged in providing topical and transdermal cannabis products under the "Ovation" brand label. It utilizes the patented "Invisicare" delivery technology, which it acquired for exclusive use for cannabis-formulated products. The group has two geographical segments: Canada and the United States. Key revenue is generated from Canada.
Executives
Shane Dungey Director
Doreen Mcmorran Director
Ian Howard Director
David K. Ryan Director

Ovation Science Headlines

No Headlines